Key result
Fenofibrate cuts plasma triglycerides ~60% in mice via enhanced clearance despite compensatory VLDL-TG overproduction.
Why the study?
The effect of fenofibrate on VLDL triglyceride production is controversial and requires detailed investigation to understand its triglyceride-lowering mechanism.
In a human-like mouse model of lipoprotein metabolism, fenofibrate decreases plasma triglycerides by enhancing LPL-mediated clearance, which triggers a compensatory increase in hepatic VLDL-TG production.
No takes yet. Share an insight, caveat, or question.
Highlights potential compensatory hepatic responses to fenofibrate; leaves open net effects on human triglyceride homeostasis.
Bijland et al. (2010) studied Hypertriglyceridemia. Fenofibrate vs. Western-type diet without fenofibrate was evaluated on Plasma triglycerides and VLDL-TG production/clearance. Fenofibrate decreased plasma triglycerides by 60% by enhancing LPL-mediated VLDL-TG clearance, which resulted in a compensatory 73% increase in VLDL-TG production by the liver in mice.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: